HHV-8 vIRF interactions in the context of infection

HHV-8 vIRF 在感染情况下的相互作用

• 批准号: 8994365
• 负责人: John Nicholas
• 金额: $ 17.62万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-01 至 2017-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8994365
• 关键词: Address; Affinity; Antiviral Agents; Apoptosis; Apoptotic; Ataxia-Telangiectasia-Mutated protein kinase; BCL2 gene; Binding; Biological; Biology; Cell Cycle Arrest; Cell Survival; Cells; Clinical; Cytostatics; Data; Development; EP300 gene; Endothelial Cells; Evaluation; Family; Genes; Genetic Transcription; Goals; Homologous Gene; Human Herpesvirus 8; Immune; Immune response; Individual; Infection; Interferons; Kaposi Sarcoma; Knowledge; Latent Virus; Life Cycle Stages; Lymphoma; Macaca mulatta; Malignant - descriptor; Malignant Neoplasms; Mass Spectrum Analysis; Mediating; Multicentric Angiofollicular Lymphoid Hyperplasia; Natural Immunity; Pathogenesis; Pathway interactions; Peptides; Phase; Precipitation; Production; Proteins; Reagent; Reporting; Research; Rhadinovirus; Role; Specific qualifier value; Stress; Surveys; Therapeutic; Therapeutic Effect; Time; Tretinoin; Viral; Viral Proteins; Virus; Virus Diseases; Virus Latency; Work; base; cellular targeting; in vivo; inhibitor/antagonist; lytic replication; member; novel; overexpression; prevent; primary effusion lymphoma; public health relevance; response; viral interferon regulatory factor; viral interferon regulatory factor-1

 DESCRIPTION (provided by applicant): Human herpesvirus 8 (HHV-8) specifies four viral interferon regulatory factor homologues (vIRFs) that represent a novel set of virus-encoded proteins, so-far identified only in HHV-8 and closely related rhesus rhadinovirus. The HHV-8 vIRFs function to inhibit cellular IRF activities and other components of cellular defense pathways that promote cell cycle arrest and apoptosis in response to virus infection. Two of the vIRFs, vIRF-1 and vIRF-3, have been demonstrated to contribute significantly to either virus productive replication (in endothelial cells) or to latently infected cell viability [in primary efusion lymphoma (PEL) cells]; each vIRF is expressed during both latent (PEL) and lytic replication. Both phases of the virus life cycle are important for HHV-8 malignant pathogenesis: Kaposi's sarcoma, PEL, and multicentric Castleman's disease. Known targeted cellular proteins of vIRF-1 include IRFs, p300/CBP transcriptional co-activators required for IRF-mediated responses, IFN/retinoic acid-induced GRIM19, p53, p53-activating ATM kinase, and certain BH3-only (pro-apoptotic) members of the Bcl-2 family; vIRF-3 targets IRFs, p300/CBP, and p53. However, the full repertoire of inhibitory interactions of these pleiotropic proteins is far from clear and the interactions have not been adequately surveyed in the context of latent and lytic replication. Whilst we have determined that vIRF-1 interactions with BH3-only proteins are critical for successful productive replication in endothelial cells, the roles of other vIRF-1 interactions in lytic replication in these and other cells and the contributions of vIRF-1 and its interactions to PEL latency remain unknown. Similarly, the roles of vIRF-3 and its interactions in productive replication and of specific vIRF-3 interactions in latency remain to be determined. To address these issues, we propose to: (1) undertake affinity precipitations of vIRFs 1 and 3 from latently infected PEL and lytically infected PEL and endothelial cells followed by mass spectrometry analysis of co-precipitated cellular proteins; (2) use suppression, overexpression, and binding-competition analyses to identify the contributions of vIRFs 1 and 3, their cellular targets, and particular vIRF-protein interactions to latently infected cell viability and productive replication and to develop inhibitory agents. The project comprises a broadly-visioned but conceptually and experimentally focused analysis of unique viral innate immune evasion proteins whose functional and mechanistic contributions to virus biology are presently unclear. As these proteins are centrally important to both latency and productive replication, information generated from this study could provide the basis for development of novel antiviral and clinical therapies.

 描述(申请人提供)：人类疱疹病毒8型(HHV-8)指定四个病毒干扰素调节因子同源(VIRF)，它们代表一组新的病毒编码蛋白，到目前为止只在HHV-8和密切相关的恒河猴大疱疹病毒中被鉴定。HHV-8vIRFs的功能是抑制细胞IRF活性和细胞防御途径的其他组成部分，这些途径促进细胞周期停滞和细胞凋亡，以应对病毒感染。其中两个vIRF，vIRF-1和vIRF-3，已被证明对病毒的生产性复制(在内皮细胞中)或对潜伏感染的细胞存活(在原代eFusion淋巴瘤(PEL)细胞中)有显著贡献；每个vIRF在潜伏(PEL)和裂解复制期间都有表达。病毒生命周期的两个阶段对HHV-8恶性发病机制都很重要：卡波西氏肉瘤、PEL和多中心Castleman病。已知的vIRF-1靶向细胞蛋白包括IRFs、IRF介导的反应所需的p300/CBP转录共激活因子、干扰素/维甲酸诱导的GRIM19、P53、P53激活的ATM激酶以及某些BH3-BH3(促凋亡)家族成员；vIRF-3靶向IRFs、p300/CBP和P53。然而，这些多效性蛋白质的抑制相互作用的完整谱系还远不清楚，而且在潜伏复制和裂解复制的背景下，这些相互作用还没有得到充分的研究。虽然我们已经确定vIRF-1与BH3-Only蛋白的相互作用对于内皮细胞成功的有效复制至关重要，但其他vIRF-1相互作用在这些细胞和其他细胞的裂解复制中的作用以及vIRF-1及其相互作用对PEL潜伏期的贡献仍不清楚。同样，vIRF-3及其相互作用在生产性复制中的作用以及特定的vIRF-3相互作用在潜伏期中的作用仍有待确定。为了解决这些问题，我们建议：(1)从潜伏感染的PEL和裂解感染的PEL和内皮细胞中进行virf 1和3的亲和沉淀，然后对共沉淀的细胞蛋白进行质谱分析；(2)使用抑制、过度表达和结合竞争分析来确定virf 1和3、它们的细胞靶点以及特定的virf-蛋白质相互作用对潜伏感染的细胞存活和有效复制的贡献。 并开发抑制剂。该项目包括对独特的病毒先天免疫逃避蛋白进行广泛的、但概念上和实验上集中的分析，这些蛋白对病毒生物学的功能和机制贡献目前尚不清楚。由于这些蛋白质对潜伏期和生产性复制都是核心重要的，这项研究产生的信息可能为开发新的抗病毒和临床疗法提供基础。